Moving into the new era of ‘Wellcare’
It has long been our vision to make disease a thing of the past, but in order to get there, we know healthcare across our region needs to adapt and evolve into a sustainable and resilient ecosystem, prepared for the next generation of therapies.
In future, a physician’s focus will be on keeping someone in good health and taking pre-emptive steps to do so, instead of only treating conditions once someone is already sick. We are going beyond early detection to focus on disease interception. This is what we call the ‘wellcare era’ – keeping people from getting sick in the first place.
This era is already emerging through cutting-edge technologies in cell and gene therapy, advances in data science powered by AI, and revolutionary patient solutions that empower people to take an active role in their health.
But as this new approach to healthcare becomes a reality, we have to assess the economic and social realities of our current system and ask ourselves: are we prepared for it?
Janssen’s focus: digital healthcare innovation
Recent global events, including the COVID-19 pandemic, have put healthcare in the spotlight, revealing many areas where collaboration is essential if we are to progress. At Janssen, our focus is always on ensuring patients get the best possible outcomes. And we believe the current wave of digital healthcare solutions can help achieve the ‘triple aim’ of improving an individual’s experience of care, improving the health of populations and reducing the per capita costs of care.
Among many others, two areas of digital innovation where we are partnering with others to make a meaningful difference for tomorrow are in Real-World Evidence and Health Technology Assessment of Innovation in Cancer.
Health Technology Assessment of Innovation in Cancer
Through cell and gene therapies, the next generation of cancer breakthroughs are on the horizon, but how can we evaluate them fairly and swiftly, to ensure patients have access to these treatments?
By harnessing vast amounts of health data, we can help unlock a new body of evidence, which can increase disease understanding, help everyone in healthcare to make better decisions, and ultimately improve clinical practice and health outcomes for patients.
“With the next generation of therapies within our reach, we want to do all we can to ensure healthcare systems across our region are prepared for this shift. We cannot do this alone and welcome healthy discussion with all our stakeholders, so together we can move closer to a world where disease is a thing of the past.”
Vice President of Health Economics, Market Access and Reimbursement, Janssen Europe, Middle East and Africa